Effect of a New Formulation of Vitamin B12 on Physical and Mental

NCT ID: NCT06639789

Last Updated: 2024-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study evaluates the effect of acute intake of a new vitamin B12 formulation on anaerobic and cognitive performance variables. One of the limiting factors for the potential beneficial effects of vitamin B12 is its bioavailability. This new formula improves this aspect, so that by improving plasma levels of B12 we will be able to relate whether this situation may be related to improved performance or cognitive tasks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants

All participants were informed about the procedures and provided signed informed consent. The study was conducted in accordance with the guidelines of the Declaration of Helsinki Declaration for Research Involving Human Subjects and the protocol was approved by the Institutional Review/Ethics Committee of the Catholic University of Murcia (Code: CE052416).

Study design

Randomized, double-blind, placebo-controlled, crossover clinical trial with 2 study groups (vitamin B12 and placebo). Cyclists were instructed to take the supplement (vitamin B12 or placebo) with breakfast on the three days before the tests and 3h before the test day, and to continue with their usual diet and training programme. Subjects in both groups were instructed not to consume vitamin B12-rich foods for 7 days before and during the study. Between each intervention (B12 and Placebo) there was a 7-day washout period.

Procedures

Participants visited the laboratory on three occasions. Visit 1 consisted of a medical examination and a blood draw to determine health status. At visits 2 and 3, a 24-hour diet reminder and a Wingate test, mental fatigue test and venous blood draw were performed. The sports nutritionist prescribed a standardized breakfast before each testing session (visits 2 and 3).

Pre- and post-evaluation test

Visit 1:

Health status blood test: A general blood test will be performed both pre- and post-supplementation. The blood will be drawn through a vein (fasting).

Medical examination: A medical history of family and personal history, an electrocardiogram (ECG) at rest and a medical examination (auscultation, blood pressure, etc.) will be carried out to certify that the person is healthy and does not present a risk to participate in the study (Fasting).

Body composition by absorptiometric densitometry (DXA): A body composition test will be performed using the double energy absorptiometric densitometry technique (X-rays), with the aim of determining parameters of fat mass, fat-free mass and fat percentage. In addition, anthropometry will also be used to determine changes in body composition (fat and muscle mass) (Fasting).

Visits 2 and 3:

Anaerobic power and mechanical power output: After a standardised breakfast, a Wingate test was performed on a cycle ergometer. The Wingate test (WAnT) consisted of a 30 s sprint on a cycle ergometer (Monark Ergomedic 894E Peak Bike, Vansbro, Sweden). Breaking strength was held constant at 7.5% of each individual's body mass. All participants were verbally encouraged to pedal as fast as possible throughout the sprint.

Mental fatigue test: All participants will be tested for the evaluation of reaction time to a sequence of lights set by the investigator before and after the performance test.

Biochemical markers: A venous blood draw will be performed by medical personnel before and after the performance test, in which vitamin B12, creatine kinase and lactate dehydrogenase levels will be analyzed.

All data of the subjects who participated in the study were stored in a computer system with a security key. In addition, some of the data was also recorded on paper and kept under lock and key, accessible only to the researchers of this project.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Performance Enhancing Product Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A randomized crossover study will be conducted in which 18 subjects will perform the following conditions: B12) 1 mg/d vitamin B12; PLA) 200 mg/d placebo (microcrystalline cellulose) 3 days before physical and cognitive performance tests.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin B12 (B12)

Subjects in this group will intake 1 mg/day of vitamin B12 three days before the tests.

Group Type EXPERIMENTAL

Vitamin B12 (B12)

Intervention Type DIETARY_SUPPLEMENT

The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).

PLACEBO (PLA)

Subjects in this group will intake 200 mg/day of microcrystalline cellulose three days before the tests.

Group Type PLACEBO_COMPARATOR

PLACEBO (PLA)

Intervention Type DIETARY_SUPPLEMENT

The placebo will be ingested 3 days before and the same day of the tests (3 hours before).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin B12 (B12)

The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).

Intervention Type DIETARY_SUPPLEMENT

PLACEBO (PLA)

The placebo will be ingested 3 days before and the same day of the tests (3 hours before).

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male cyclists who have competed in both junior and amateur categories.
* Cycling between 6-15 hours of training per week.
* BMI between 18-25 kg/m2.

Exclusion Criteria

* Smokers or regular alcohol drinkers.
* Persons suffering from a metabolic, cardiorespiratory or digestive pathology or anomaly.

digestive system.

* People who have suffered an injury in the last 6 months that limits the performance of the study tests. of the study tests.
* People taking supplements or medication in the 2 weeks before the start of the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Católica San Antonio de Murcia

OTHER

Sponsor Role collaborator

Francisco Javier Martínez Noguera

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Francisco Javier Martínez Noguera

PhD (Head of the nutrition area of the Research Center for High Performance Sport)

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francisco Javier J Martínez Noguera

Role: STUDY_CHAIR

Research Center for High Performance Sport. Catholic University of Murcia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Center for High Performance Sport. Catholic University of Murcia

La Ñora, Murcia, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Francisco Javier FJ Martínez Noguera, PhD

Role: CONTACT

(+34) 968278566

Cristian C Marín Pagán, PhD

Role: CONTACT

(+34) 968278566

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Francisco Javier Martínez Noguera, PhD

Role: primary

(+34) 646666782

Cristian Marín Pagán, PhD

Role: backup

(+34) 968278566

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CE052416

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin B12 Supplementation Study
NCT00826657 COMPLETED NA
Effects of Vitamin B12 Treatment in Singers
NCT03437824 COMPLETED EARLY_PHASE1
Early Infant Micronutrition and Development
NCT05005897 RECRUITING PHASE2/PHASE3